Surevest’s Bristol-Myers Squibb BMY Stock Holding History

Surevest’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$3.76M	Sell	52,849 -285	-0.5%	-$20.7K	1.02%	33
2022 Q2	$4.09M	Buy	53,134 +487	+0.9%	+$37.1K	1.07%	28
2022 Q1	$3.85M	Sell	52,647 -13,464	-20%	-$904K	0.93%	41
2021 Q4	$4.12M	Sell	66,111 -6,788	-9%	-$398K	0.98%	48
2021 Q3	$4.31M	Buy	72,899 +6,564	+10%	+$432K	1.09%	48
2021 Q2	$4.43M	Sell	66,335 -2,835	-4%	-$185K	1.16%	44
2021 Q1	$4.37M	Buy	69,170 +7,621	+12%	+$474K	1.32%	35
2020 Q4	$3.82M	Buy	61,549 +3,979	+7%	+$245K	1.27%	43
2020 Q3	$3.47M	Buy	57,570 +4,152	+8%	+$250K	1.36%	33
2020 Q2	$3.14M	Buy	53,418 +5,080	+11%	+$304K	1.39%	28
2020 Q1	$2.69M	Buy	48,338 +16,027	+50%	+$980K	1.47%	17
2019 Q4	$2.07M	Buy	32,311 +12,978	+67%	+$743K	0.89%	50
2019 Q3	$980K	Buy	19,333 +4,716	+32%	+$222K	0.48%	80
2019 Q2	$663K	Buy	14,617 +8,008	+121%	+$373K	0.34%	97
2019 Q1	$315K	Buy	6,609 +1,383	+26%	+$68.9K	0.19%	102
2018 Q4	$272K	Buy	+5,226	New	+$281K	0.21%	101

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Surevest's BMY Position: Q3 2022 in Review

Surevest reduced its Bristol-Myers Squibb (BMY) stake by 0.54% in Q3 2022, selling an estimated $20.7K and leaving 52,849 shares worth $3.76M. The position accounts for 1.02% of the portfolio, ranked #33.

Surevest first reported a position in BMY in Q4 2018 and has held it in 16 quarters since. The position peaked at $4.43M in Q2 2021. 2,469 funds tracked by Wall St. Rank hold BMY as of Q3 2022.

Surevest held 52,849 shares of Bristol-Myers Squibb worth $3.76M as of Q3 2022.
Surevest sold 285 Bristol-Myers Squibb shares in Q3 2022, an estimated $20.7K.
Bristol-Myers Squibb made up 1.02% of Surevest's portfolio in Q3 2022, its #33 holding.
Surevest first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 16 quarters since.
Surevest's Bristol-Myers Squibb position peaked at $4.43M in Q2 2021.
2,469 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.

Based on Surevest's 13F filing for Q3 2022, filed 14 Nov 2022.